LYCOS RETRIEVER 
Organon
built 623 days ago
Organon is a pharmaceutical multinational with over 14.000 employees worldwide, spread out over offices in sixty countries. One owns research facilities in 5 countries, production facilities in 15 countries and sales offices in 50 countries. The medications are available in over one hundred countries. RGN was given the task to look after the complete restyling. This involves not just its fleet, illuminated advertising, road indicators but ... involves clothes, print, digital media, intranet and internet. The new corporate identity will also be found on packaging, which is distributed worldwide.
Source:
The most high profile of Organon's drugs is the antipsychotic asenapine, tentatively slated for launch later this year. It was previously being developed in conjunction with Pfizer, who pulled out of the collaboration last year following mixed clinical trial results. Asenapine is intended as a treatment for the symptoms of schizophrenia and the acute mania associated with bipolar disorder, which affect about one per cent of people worldwide. It aims to tackle the incoherence experienced by patients, even when their hallucinations are being effectively treated with traditional therapies. It has plenty of competition from experimental drugs with the same goal, but Organon hopes that its unique mode of action will set it apart. The molecule acts on both serotonin (5HT-2a) receptors and dopamine (D2) receptors, blocking the former and partially stimulating the latter.
Source:
"Organon, now part of Schering-Plough Corporation, has had a strong presence in the anesthesia market for over 35 years," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "The development of sugammadex is an exciting advance for the practice of anesthesia. This novel drug has the potential to change the way doctors practice anesthesia as it will allow anesthesiologists to rapidly and safely reverse both shallow and profound levels of muscle relaxation, which is not possible with current reversal agents."
Source:
SRI Organon meets every Tuesday from 11:45 to 1:00pm, except on holidays, at SRI International in Menlo Park. Club members come from many different backgrounds, membership is not restricted, and guests are always welcome. The meetings are held in G. Building located off Laurel Avenue (get directions). Occasionally the meeting location changes, so please call ahead for more information.
Source:
PRINCETON, N.J., and OSS, The Netherlands, Feb. 1 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) and Organon, the human health care business unit of Akzo Nobel, today announced an agreement for the development of therapeutic antibodies. Organon intends to use Medarex's UltiMAb Human Antibody Development System(R), which allows for the discovery of fully human antibodies in mice, to generate therapeutic antibodies against a variety of disease targets discovered by Organon and/or its alliance partners in discovery research. Financial terms were not disclosed. Under the terms of the agreement, Organon plans to develop and commercialize fully human antibody therapeutics. Medarex expects to receive license fees and milestone payments as well as royalties on commercial sales of any products that may result from this agreement. "We are pleased that Organon plans to combine their product development experience with our UltiMAb technology to develop novel therapeutics," said Donald L. Drakeman, President and CEO of Medarex.
Source:
Organon was founded in 1923 and is now a business unit of the healthcare group of Akzo Nobel N.V. Today, Organon has more than 13,000 employees worldwide. Akzo Nobel N.V., based in the Netherlands, serves customers throughout the world with healthcare products, coatings, and chemicals. Organon is the human healthcare business. Intervet is one of the world's top three producers of animal healthcare products. Operating independently under the Organon umbrella is Diosynth, a technology-based manufacturer of active pharmaceutical ingredients for the third-party market.
Source:
MORE ABOUT
Organon